Harvey D. White, MB; Gabriel I. Barbash, MD; Michaela Modan, PhD; John Simes, MD; Rafael Diaz, MD; John R. Hampton, MD; Juhani Heikkila, MD; Arni Kristinsson, MD; Spiros Moulopoulos, MD; Ernesto A.C. Paolasso, MD; Tyeerd Van der Werf, MD; Kenneth Pehrsson, MD; Erik Sand0e, MD; Robert G. Wilcox, MD; Marc Verstraete, MD; Gerhard von der Lippe, MD; Frans Van de Werf, MD; for the Investigators of t...

RIFM fragrance ingredient safety assessment, α-amylcinnamaldehyde, CAS registry number 122-40-7 A.M. Api a, D. Belsito b, S. Bhatia a, M. Bruze c, P. Calow d, M.L. Dagli e, W. Dekant f, A.D. Fryer g, L. Kromidas a,*, S. La Cava a, J.F. Lalko a, A. Lapczynski a, D.C. Liebler h, Y. Miyachi i, V.T. Politano a, G. Ritacco a, D. Salvito a, J. Shen a, T.W. Schultz j, I.G. Sipes k, B. Wall a, D.K. Wil...

RIFM fragrance ingredient safety assessment, Linalyl hexanoate, CAS Registry Number 7779-23-9 A.M. Api a, D. Belsito b, S. Bhatia a, M. Bruze c, P. Calow d, M.L. Dagli e, W. Dekant f, A.D. Fryer g, L. Kromidas a,*, S. La Cava a, J.F. Lalko a, A. Lapczynski a, D.C. Liebler h, Y. Miyachi i, V.T. Politano a, G. Ritacco a, D. Salvito a, J. Shen a, T.W. Schultz j, I.G. Sipes k, B. Wall a, D.K. Wilcox a

266. Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies Sailaja Puttagunta, MD; Helen Boucher, MD, FIDSA; George Talbot, MD; Mark Wilcox, MD; Michael Dunne, MD; Durata Therapeutics, Branford, CT; Tufts New England Medical Center, Boston, MA; Talbot Advisors LLC, Anna Maria, FL; Microbiology, Leeds T...

A. Michael Lincoff, MD Neal S. Kleiman, MD Dean J. Kereiakes, MD Frederick Feit, MD John A. Bittl, MD J. Daniel Jackman, MD Ian J. Sarembock, MB, ChB David J. Cohen, MD Douglas Spriggs, MD Ramin Ebrahimi, MD Gadi Keren, MD Jeffrey Carr, MD Eric A. Cohen, MD Amadeo Betriu, MD Walter Desmet, MD Wolfgang Rutsch, MD Robert G. Wilcox, MD Pim J. de Feyter, MD Alec Vahanian, MD Eric J. Topol, MD for t...

I would like to express my sincere gratitude to Bradford DeLong, Richard Lyons, and James Pierce for their encouragement and helpful comments. I benefited greatly from discussion with Roger Craine, Maurice Obstfeld, Keiichi Hori, and James Wilcox. My special thanks also go to Sachiko Kuroda Nakada, Masaki Nakahigashi, and Yoichi Kita for providing me with the data. Of course, any remaining erro...

Introduction One of the problems encountered in the treatment of hypertension is that the long duration of therapy coupled with multiple dosage regimens in asymptomatic patients lead to poor compliance (Sackett and Haynes, 1976). Once-daily treatment regimens with P-adrenoceptor blockers other than metoprolol have been shown to be effective (Wilcox, 1978; Watson, Stallard and Littler, 1980). It...